Compare Akamai Technologies, Inc. (AKAM) vs ResMed Inc. (RMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Akamai Technologies, Inc. vs ResMed Inc. — how do they compare? Akamai Technologies, Inc. trades at $125.73 (market cap $16.63B), while ResMed Inc. trades at $206.94 (market cap $31.88B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.09% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | RMD | |
|---|---|---|
Market Cap | $16.63B | $31.88B |
Sector | Technology | Health |
52-Week High | $161.14 | $293.73 |
52-Week Low | $70.53 | $182.82 |
Enterprise Value | $21.56B | $31.06B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
ResMed (RMD) trades at $219.75, up 4.83% on the day, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust fundamentals with 2025 revenue of $5.15B and net income of $1.40B, supported by a 27.44% net margin. Recent strategic moves include the sale of MatrixCare for $490M and the acquisition of Noctrix Health, sharpening focus on core sleep and respiratory care markets.
Outlook remains positive with a consensus price target of $267.33 implying 21.6% upside, though risks include competitive pressures and integration challenges from recent M&A. The stock's current valuation at 21.06 P/E appears reasonable given growth prospects, but investors should monitor execution on guidance and market share retention amid emerging threats like GLP-1 drugs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
